PetMed Express Inc (PETS)
NASDAQHealth CareSpecialty RetailSnapshot 2026-09-04
$1.81-2.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareSpecialty RetailSnapshot 2026-09-04
Broken: Primary pillar broken — Net income improves to no worse than negative $4.1M by 2026-Q4: EPS -0.28 vs target -4.1M.
PetMed Express is cutting losses, improving operating income from negative $34.1M to negative $5.7M by 2026-Q4. The company aims to reduce net losses from negative $34.2M to negative $4.1M in the same period. Cost savings of $6.1M annually support this progress. Revenue is expected near $95M in 2025, showing some stability.
Revenue is declining and expected to fall about 12% next year. The company remains loss-making with negative cash flow. Management is volatile and recent earnings missed expectations. The stock is down 19% from its high, reflecting these risks.
The market prices the stock about 56% below our fair value near $4, expecting about 12% revenue decline. Our view aligns with the cautious outlook but sees potential if losses shrink as planned.
Breaks if: Operating cash flow worse than negative $4.7M in 2026-Q4
Breaks if: Net income worse than negative $4.1M in 2026-Q4
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with high risk. The company is currently loss-making and has shown mixed results in stabilizing its core business and expanding its market footprint.
The market appears to have priced in a low expectations gap, indicating that investors are cautious about future performance. Valuation is seen as cheap compared to peers, but the overall confidence in the model is low.
Fundamentals are likely to remain challenged in the near term, with a high probability of an earnings miss based on recent performance trends. Management has made some progress in cost reduction, but revenue continues to decline.
The long-term thesis hinges on management's ability to stabilize the business and successfully expand into new markets. Additionally, the performance of sector bellwether WRBY could influence PETS' trajectory.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
Mixed, the news cuts both ways. The company is improving operating income and reducing net losses. It also plans a $37 million sale-leaseback to unlock value. However, the latest earnings report showed a significant miss.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on reducing net losses and improving operating income through cost control and operational improvements.
Stated as a priority in 3 of last 3 quarters. Net loss improved significantly from $34.2M in 2025-Q2 to $6.1M in 2026-Q2, and operating income loss narrowed from $(34.1)M to $(6.2)M. Management is delivering on reducing losses and improving operating income.
“Net loss for the quarter ended June 30, 2026, was $6.1 million compared to $34.2 million for the prior year period.”
“Net loss of $4.1 million compared to $11.6 million for the prior year period.”
“Loss from operations improved to $(5.7) million from $(6.0) million prior year quarter.”
Breaks if: Operating income worse than negative $5.7M in 2026-Q4
Focus on reducing net losses and improving operating income through cost control and operational improvements.
Stated as a priority in 3 of last 3 quarters. Net loss improved significantly from $34.2M in 2025-Q2 to $6.1M in 2026-Q2, and operating income loss narrowed from $(34.1)M to $(6.2)M. Management is delivering on reducing losses and improving operating income.
“Net loss for the quarter ended June 30, 2026, was $6.1 million compared to $34.2 million for the prior year period.”
“Net loss of $4.1 million compared to $11.6 million for the prior year period.”
“Loss from operations improved to $(5.7) million from $(6.0) million prior year quarter.”
Breaks if: Revenue falls below $83.6M in FY26
Maintain revenue stability despite declines in prescription medication sales and fluctuating consumer demand.
Stated as a priority in 2 of last 2 quarters. Revenue declined from $51.2M in 2025-Q2 to $41.0M in 2026-Q2, a 19.9% decrease, mainly due to lower prescription medication sales. Management highlights sequential stabilization but revenue remains challenged, indicating limited progress on stability.
“Net sales demonstrated sequential quarterly stabilization despite a 19.9% decrease year-over-year.”
“Net sales of $42.8 million compared to $50.8 million in the prior year period, a decrease of 15.6%.”
In the next 1 to 3 years, PETS must navigate significant operational challenges while leveraging sector momentum. Not investment advice.